Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. - Wikidata - awgldk - TriplyDB

Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.

Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q41031903

about

Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies.Muscle fatigue, nNOS and muscle fiber atrophy in limb girdle muscular dystrophy Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy Recent advances using zebrafish animal models for muscle disease drug discovery Mimicking Cardiac Fibrosis in a Dish: Fibroblast Density Rather than Collagen Density Weakens Cardiomyocyte Function Sildenafil increases muscle protein synthesis and reduces muscle fatigue.PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling.Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.Sarcolemmal targeting of nNOSμ improves contractile function of mdx muscle.Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition Matrix metalloproteinase 13 is a new contributor to skeletal muscle regeneration and critical for myoblast migration.Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A.Therapeutic advances in muscular dystrophy Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice.Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation.Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy.GSNOR Deficiency Enhances In Situ Skeletal Muscle Strength, Fatigue Resistance, and RyR1 S-Nitrosylation Without Impacting Mitochondrial Content and Activity.Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.Immune-mediated pathology in Duchenne muscular dystrophy.The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases A change of heart: oxidative stress in governing muscle function?Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy.Dystrophin: The dead calm of a dogma.Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation.

P2860

Q26772002-EB2831FA-ED82-4795-8C61-577ACA607CBD Q26785627-60EFB345-F78B-491D-9B9F-DCB1350D64B9 Q27028125-2F87F932-4FFA-4E01-8448-4CE0B40BB366 Q28083989-BFD59C1A-7A1E-404C-A4A0-5786E2161D0E Q28484851-B4658FAE-9A0A-495D-B08C-961C6DED2152 Q28550201-76F4C9A3-72BF-48B2-96E3-CD838444319F Q28551915-6E078486-7806-42F6-BC52-C3BB0BD50972 Q33705089-E9C19FAA-AFB0-4B59-845A-32AA2ED73D99 Q33827719-C5DCEF6F-E470-431D-83A6-1BD6BAE7DA18 Q33987140-F5FBEC89-60AD-4850-A87F-1B4154FC0C5A Q33991780-736B6752-4EDA-4CC5-9532-D5D3725B21C6 Q34152280-5EEC3C38-D110-4277-B436-18E0AEE6DBD8 Q34315276-6B491B95-A902-43BE-98BC-F9C76D8DA2F3 Q34755463-116BEF7E-EF6A-46DC-947B-82F0A70F9B10 Q34764061-41507E40-E916-40E4-AC85-A7B2CC141F75 Q35043351-9D1C3F9F-92D5-4F7F-A285-73FFA1A62078 Q35901453-E8CE6507-BC74-4868-AF59-971E4C76ED64 Q36179162-A5CFB195-E8A8-4B44-A4A4-D3F932D4415D Q36402599-619B08CE-B91B-445D-9603-BF2E9F7F1BCD Q36422465-FA23D50D-25EC-43F1-BE8A-1865DD6254C1 Q36467072-3FCA8BD3-A746-4A56-8F15-BAB1C787844E Q37142364-25F37F57-CA58-40E5-8978-19219943CF14 Q37240478-2D42751A-91B6-41ED-A77F-960760E7547C Q37307216-A6FC69D7-20B3-4BF3-8419-5ECE407BB0D1 Q37455625-222FC03B-1770-4274-A58F-BEF4C076F1A7 Q37539643-7A27CE15-F322-44E3-86E3-0A7EF48A60BC Q37589790-65E6FA30-AD94-44FF-AB64-2B4562D87991 Q37657529-29517AE4-BDEA-491F-A6CF-061C3EEF2D06 Q38264461-2183AD76-80A9-41C6-8AB2-8192664447F8 Q38412593-C9E0470C-9A44-4607-AF02-4CDA34DE9D17 Q38412804-F2620734-3AA7-4A39-9950-E998F5EC3742 Q38561435-CF44C600-98CD-4CF2-9BC8-A62DE3F4423D Q39211384-FA2C0B16-A706-40B4-B21A-8D5F7DEA7CC4 Q39310989-C3ECED0F-DF31-4968-8E2A-53A5AD6B7823 Q39330717-21CAC14C-DF27-407F-A05F-648B631D8512 Q39410461-03744873-EFA7-417D-9CBF-D0E936AD329B Q40401831-F0357C3B-0471-46B5-B1C3-9E47228E70C6 Q40401861-8A1451E3-0491-479A-BAF7-58B0B82171F2 Q40603890-EFE06007-068C-460A-8005-090FAEF5AA3D Q42339913-A75C3606-8BE8-4A9B-983E-05405AC6F1D8

P2860

Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q41031903

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Sildenafil reduces respiratory ...... f Duchenne muscular dystrophy.

@en

type

label

Sildenafil reduces respiratory ...... f Duchenne muscular dystrophy.

@en

prefLabel

Sildenafil reduces respiratory ...... f Duchenne muscular dystrophy.

@en

P1433

Q41031903-5C43C8F4-A7CF-46CA-BC5A-1C9751166769

P1476

Q41031903-770D6FF1-2BB1-42A9-B3D5-772F156F061D

P2093

Q41031903-466961FD-E329-4A2F-A5E2-3B9EDE7201F2

Q41031903-49A94254-E8F3-4F31-AFB9-E80CC84F50AB

Q41031903-7E551611-1846-4BB6-8E9B-B89A4F375DF2

Q41031903-99E7CA28-3DC2-436D-A064-F9F87F1E7840

Q41031903-AB9BB3CC-DD4D-415D-8363-41ABDF3852D9

Q41031903-DC474D84-CE0A-42FE-BD28-707E340D664A

P2860

Q41031903-001A68EF-DB9B-4541-B14C-F6F53D1017CC

Q41031903-01A12390-AD9F-46FA-98FC-BE6E74B6EB27

Q41031903-05F1B833-5355-4B94-9C40-22788702EDA0

Q41031903-0695E8E8-A011-40AC-AF0F-549E89BEEAFD

Q41031903-0C48D7A0-7CDA-4646-B5D4-69FA662313F9

Q41031903-0C5AEB0C-6E26-435C-ABCA-C1D571832FF0

Q41031903-0CA93AC3-BE97-43CE-9B42-CD0960A6DBBB

Q41031903-0F642B95-DACF-4BD7-A71C-F9EA43D6B652

Q41031903-1E66751B-CC89-4311-95E3-802F169C53E8

Q41031903-2302695F-1AEF-4D90-8A3D-9767BC692668

P304

Q41031903-E7E5CB53-F5E4-4DA7-A85F-AB1615E72BAF

P31

Q41031903-E404741F-7EC6-4FF8-BBDC-BD93147C5664

P356

Q41031903-48B87311-F526-42F4-800C-1A37F480C2DC

P433

Q41031903-E30546EE-8951-4DD7-993D-BF68311CC0EE

P478

Q41031903-4E331477-F2CB-4000-9153-0E2A421F040F

P577

Q41031903-7F225FB0-AAB1-4F8D-B114-0CABC091A5B8

P5875

Q41031903-8C710AF8-9EFA-4EA6-A402-FE150D9CAA31

P698

Q41031903-AB4A4E9B-CD3B-449B-9AF6-4FAFC3DD34F3

P932

Q41031903-703F95EB-62F3-4669-84CA-3981A3E7600F

P356

P1433

The Journal of Pathology

P1476

Sildenafil reduces respiratory ...... f Duchenne muscular dystrophy.

@en

P2093

Candace M Adamo

http://www.w3.org/2001/XMLSchema#string

Joseph A Beavo

http://www.w3.org/2001/XMLSchema#string

Justin M Percival

http://www.w3.org/2001/XMLSchema#string

Marvin E Adams

http://www.w3.org/2001/XMLSchema#string

Nicholas P Whitehead

http://www.w3.org/2001/XMLSchema#string

Stanley C Froehner

http://www.w3.org/2001/XMLSchema#string

P2860

Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy

Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency

Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy

The structure, regulation, and function of human matrix metalloproteinase-13

Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal Nitric oxide synthase

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

Comparison of mouse matrix metalloproteinase 13 expression in free-electron laser and scalpel incisions during wound healing.

Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice

Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice

Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle

P304

77-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.4054

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

228

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225088339

http://www.w3.org/2001/XMLSchema#string

P698

22653783

http://www.w3.org/2001/XMLSchema#string

P932

4067455

http://www.w3.org/2001/XMLSchema#string